⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4991113 | 0.83 | NOS1 (0.32) | — | |
| SCHEMBL400865 | 0.77 | GFER (0.68) | — | |
| SCHEMBL2642759 | 0.77 | TAAR1 (0.56) | — | |
| SCHEMBL2642245 | 0.75 | HRH3 (0.58) | — | |
| 4,4'-Methylenedianiline SCHEMBL28001 | 0.73 | CYP3A4 (1.00) | — | |
| SCHEMBL3482770 | 0.73 | CYP3A4 (1.00) | — | |
| SCHEMBL6362775 | 0.73 | CYP3A4 (1.00) | — | |
| SCHEMBL8094139 | 0.73 | CYP3A4 (1.00) | — | |
| SCHEMBL3482833 | 0.73 | GFER (1.00) | — | |
| SCHEMBL1304762 | 0.73 | CYP3A4 (1.00) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220211701-A1 | TREATMENT OF CANCER UTILIZING AN IDENTIFIED ADENOSINE FINGERPRINT | ARCUS BIOSCIENCES, INC. (US) | 2022-07-07 | — | — | US | claimed |
| CN-114395005-A | Modulators of extracellular 5' -nucleotidase and uses thereof | 艾库斯生物科学有限公司 | 2022-04-26 | — | — | CN | claimed |
| CN-113874397-A | Treatment of cancer using identified adenosine fingerprints | 艾库斯生物科学有限公司 | 2021-12-31 | — | — | CN | claimed |
| CN-113795267-A | Oncogene driven treatment of cancer | 艾库斯生物科学有限公司 | 2021-12-14 | — | — | CN | claimed |
| EP-3761993-A1 | PARENTERALLY ADMINISTERED IMMUNE ENHANCING DRUGS | Arcus Biosciences, Inc. (US) | 2021-01-13 | — | — | EP | claimed |
| US-20200405629-A1 | PARENTERALLY ADMINISTERED IMMUNE ENHANCING DRUGS | ARCUS BIOSCIENCES, INC. | 2020-12-31 | — | — | US | claimed |
| CN-112004541-A | Immunopotentiating medicine for parenteral administration | 艾库斯生物科学有限公司 | 2020-11-27 | — | — | CN | claimed |
| US-20190309010-A1 | MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF | ARCUS BIOSCIENCES, INC. | 2019-10-10 | — | — | US | claimed |
| WO-2019173682-A1 | PARENTERALLY ADMINISTERED IMMUNE ENHANCING DRUGS | ARCUS BIOSCIENCES, INC. (US) | 2019-09-12 | — | — | WO | claimed |
| US-10239912-B2 | Modulators of 5′-nucleotidase, ecto and the use thereof | ARCUS BIOSCIENCES, INC. (US) | 2019-03-26 | — | — | US | claimed |
| EP-3399984-A1 | MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF | Arcus Biosciences, Inc. (US) | 2018-11-14 | — | — | EP | claimed |
| US-20170267710-A1 | MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF | ARCUS BIOSCIENCES, INC. | 2017-09-21 | — | — | US | claimed |
| WO-2017120508-A1 | MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF | ARCUS BIOSCIENCES, INC. (US) | 2017-07-13 | — | — | WO | claimed |
| EP-2142518-B1 | 3,4-DIHYDROQUINAZOLINE DERIVATIVES | DONGWOO SYNTECH CO LTD (KR) | 2012-05-02 | — | — | EP | claimed |
| US-8168646-B2 | 3,4-dihydroquinazoline derivatives | DONGWOO SYNTECH CO., LTD. (KR) | 2012-05-01 | — | — | US | claimed |
| WO-2010139288-A1 | 5,7-DISUBSTITUTED 3-ISOPROPYLPYRAZOLO[4,3-D]PYRIMIDINES FOR USE AS MEDICAMENTS AND PHARMACEUTICAL COMPOSITIONS | C3 BIO GMBH (DE) | 2010-12-09 | — | — | WO | claimed |
| US-20100120803-A1 | 3,4-DIHYDROQUINAZOLINE DERIVATIVES | DONGWOO SYNTECH CO., LTD. (KR) | 2010-05-13 | — | — | US | claimed |
| EP-2142518-A1 | 3,4-DIHYDROQUINAZOLINE DERIVATIVES | Dongwoo Syntech Co., Ltd. (KR) | 2010-01-13 | — | — | EP | claimed |
| WO-2008136631-A1 | 3,4-DIHYDROQUINAZOLINE DERIVATIVES | DONGWOO SYNTECH CO., LTD. (KR) | 2008-11-13 | — | — | WO | claimed |
| US-20020058788-A1 | Facile deprotection of Fmoc protected amino groups | DISCOVERY PARTNERS INTERNATIONAL, INC. | 2002-05-16 | — | — | US | claimed |